Aliases & Classifications for Ureter Cancer

Aliases & Descriptions for Ureter Cancer:

Name: Ureter Cancer 12 14
Ureter Carcinoma 12 52 14 69
Ureteral Benign Neoplasm 12 14
Ureteral Neoplasms 42 69
Malignant Neoplasm of Ureter 69
Malignant Tumour of Ureter 12
Malignant Ureteral Tumor 12
Neoplasm of Ureter 12
Ureteral Carcinoma 12
Ureteral Tumor 12

Characteristics:

HPO:

32
ureter cancer:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:11819 DOID:11885 DOID:4939
ICD10 33 C66
ICD9CM 35 189.2
MeSH 42 D014516

Summaries for Ureter Cancer

Disease Ontology : 12 An ureter cancer that is located in the ureter.

MalaCards based summary : Ureter Cancer, also known as ureter carcinoma, is related to regional ureteric cancer and ureter adenocarcinoma, and has symptoms including neoplasm of the ureter An important gene associated with Ureter Cancer is PLAUR (Plasminogen Activator, Urokinase Receptor), and among its related pathways/superpathways are Endochondral Ossification and Lung fibrosis. The drugs Cisplatin and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include kidney and the ureter, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 Ureteral cancer is cancer of the ureters, muscular tubes that propel urine from the kidneys to the... more...

Related Diseases for Ureter Cancer

Diseases related to Ureter Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Related Disease Score Top Affiliating Genes
1 regional ureteric cancer 10.9
2 ureter adenocarcinoma 10.9
3 common cold 10.2 PLAU PLAUR
4 loiasis 10.2 PLAU PLAUR
5 peroneal nerve paralysis 10.1 CHGA SYP
6 thymus small cell carcinoma 10.1 CHGA SYP
7 brain stem ependymoma 10.1 CHGA SYP
8 non specific chronic endometritis 10.1 CHGA SYP
9 extrahepatic biliary papillomatosis 10.1 CHGA SYP
10 prolactin producing pituitary tumor 10.1 CHGA SYP
11 epithelioid malignant peripheral nerve sheath tumor 10.1 CHGA SYP
12 cartilage cancer 10.1 CHGA SYP
13 villous adenocarcinoma 10.1 CHGA SYP
14 jejunal neuroendocrine tumor 10.1 CHGA SYP
15 renal pelvis adenocarcinoma 10.1 CHGA SYP
16 spasmodic dysphonia 10.1 CHGA SYP
17 barre-lieou syndrome 10.1 CHGA SYP
18 microinvasive cervical squamous cell carcinoma 10.1 CHGA SYP
19 perineural angioma 10.1 CHGA SYP
20 gastric duplication cysts 10.1 CHGA SYP
21 diffuse cutaneous mastocytosis 10.1 CHGA SYP
22 main bronchus cancer 10.1 CHGA SYP
23 gliofibroma 10.1 CHGA SYP
24 cavernous hemangioma of face 10.1 CHGA SYP
25 hyperphenylalaninemia, bh4-deficient, b 10.1 CHGA MGP
26 adult botryoid rhabdomyosarcoma 10.1 CHGA SYP
27 superior vena cava syndrome 10.1 CHGA SYP
28 exudative glomerulonephritis 10.1 CHGA SYP
29 fragile x-associated tremor/ataxia syndrome 10.1 CHGA SYP
30 acalculous cholecystitis 10.1 CHGA SYP
31 piussan lenaerts mathieu syndrome 10.1 CHGA SYP
32 brain stem astrocytic neoplasm 10.1 CHGA SYP
33 anal squamous cell carcinoma 10.1 CHGA SYP
34 pemphigus vulgaris 10.1 PLAU PLAUR
35 uterine corpus myxoid leiomyosarcoma 10.1 CHGA SYP
36 calcific tendinitis 10.1 CHGA SYP
37 mitochondrial complex ii deficiency 10.1 CHGA SYP
38 bone marrow cancer 10.1 CHGA SYP
39 dysgerminoma of ovary 10.1 CHGA SYP
40 pediculus humanus corporis infestation 10.1 CHGA SYP
41 acinar cell cystadenocarcinoma 10.1 CHGA SYP
42 hunter macpherson syndrome 10.1 CHGA SYP
43 cowden syndrome 3 10.1 CHGA SYP
44 ampulla of vater mucinous adenocarcinoma 10.1 CHGA SYP
45 thymus squamous cell carcinoma 10.1 CHGA SYP
46 growth retardation hydrocephaly lung hypoplasia 10.1 CHGA SYP
47 testicular trophoblastic tumor 10.1 CHGA SYP
48 bone dysplasia azouz type 10.1 CHGA SYP
49 cardioauditory syndrome of sanchez cascos 10.1 CHGA SYP
50 pancreatic agenesis 10.1 CHGA SYP

Comorbidity relations with Ureter Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Hydronephrosis Prostatic Hypertrophy
Renal Pelvis Carcinoma Urinary Bladder Cancer

Graphical network of the top 20 diseases related to Ureter Cancer:



Diseases related to Ureter Cancer

Symptoms & Phenotypes for Ureter Cancer

Human phenotypes related to Ureter Cancer:

32
id Description HPO Frequency HPO Source Accession
1 neoplasm of the ureter 32 HP:0100516

MGI Mouse Phenotypes related to Ureter Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 MGP PLAU PLAUR ADRA1A CHGA
2 homeostasis/metabolism MP:0005376 9.63 ADRA1A CHGA MGP PLAU PLAUR TERT
3 renal/urinary system MP:0005367 9.26 ADRA1A CHGA MGP PLAUR
4 respiratory system MP:0005388 8.92 MGP PLAU PLAUR TERT

Drugs & Therapeutics for Ureter Cancer

Drugs for Ureter Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2 23214-92-8 31703
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
10
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
11
Succinylcholine Approved Phase 3,Phase 2 306-40-1 5314
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 54575, 6560146 143
14
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
15
Doxil Approved June 1999 Phase 3,Phase 1,Phase 2 31703
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1
17 Antimetabolites Phase 3,Phase 2,Phase 1
18 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
19 Antimitotic Agents Phase 3,Phase 2,Phase 1
20 Antiviral Agents Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
22 Liver Extracts Phase 3,Phase 2,Phase 1
23 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
24 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
26 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
28 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
29 Antirheumatic Agents Phase 3,Phase 2,Phase 1
30 Dermatologic Agents Phase 3,Phase 2
31 Folic Acid Antagonists Phase 3,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
33 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2
34 Vitamin B Complex Phase 3,Phase 2,Phase 1
35 Adjuvants, Anesthesia Phase 3
36 Analgesics Phase 3,Phase 1,Phase 2
37 Analgesics, Opioid Phase 3
38 Anesthetics Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Central Nervous System Depressants Phase 3
42 Narcotics Phase 3
43 pancreatic polypeptide Phase 3,Phase 1
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Early Phase 1
45 Alkylating Agents Phase 3,Phase 1,Phase 2
46 Mitomycins Phase 3
47 Antibodies Phase 3,Phase 2,Phase 1
48 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
49 Immunoglobulins Phase 3,Phase 2,Phase 1
50 Endothelial Growth Factors Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 140)
id Name Status NCT ID Phase
1 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3
2 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3
3 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) Recruiting NCT01993979 Phase 3
6 Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE) Recruiting NCT01658930 Phase 3
7 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study Recruiting NCT02793128 Phase 3
8 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3
9 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Active, not recruiting NCT02426125 Phase 3
10 Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer Unknown status NCT00003520 Phase 2
11 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2
12 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2
13 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2
14 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2
15 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2
16 Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer Unknown status NCT01126749 Phase 1, Phase 2
17 BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma Unknown status NCT02278978 Phase 2
18 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
19 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium Completed NCT00077688 Phase 2
20 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2
21 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2
22 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00101608 Phase 2
23 Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer Completed NCT00041106 Phase 2
24 Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter Completed NCT00066352 Phase 2
25 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract Completed NCT00112671 Phase 2
26 Oxaliplatin in Treating Patients With Metastatic Bladder Cancer Completed NCT00004203 Phase 2
27 Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer Completed NCT00003105 Phase 1, Phase 2
28 R115777 in Treating Patients With Advanced Bladder Cancer Completed NCT00006376 Phase 2
29 Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00310011 Phase 2
30 Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer Completed NCT00028860 Phase 2
31 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer Completed NCT00792025 Phase 2
32 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Completed NCT00080795 Phase 2
33 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy Completed NCT00066612 Phase 2
34 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00053209 Phase 2
35 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium Completed NCT00045630 Phase 2
36 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2
37 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00006351 Phase 2
38 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2
39 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer Completed NCT00004223 Phase 2
40 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2
41 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function Completed NCT00005644 Phase 2
42 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2
43 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00014144 Phase 2
44 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2
45 Arsenic Trioxide in Treating Patients With Urothelial Cancer Completed NCT00009867 Phase 2
46 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2
47 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer Completed NCT00003175 Phase 2
48 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2
49 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2
50 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2

Search NIH Clinical Center for Ureter Cancer

Cochrane evidence based reviews: ureteral neoplasms

Genetic Tests for Ureter Cancer

Anatomical Context for Ureter Cancer

MalaCards organs/tissues related to Ureter Cancer:

39
Kidney

The Foundational Model of Anatomy Ontology organs/tissues related to Ureter Cancer:

18
The Ureter

Publications for Ureter Cancer

Articles related to Ureter Cancer:

id Title Authors Year
1
Segmental ureterectomy does not compromise the oncologic outcome compared with nephroureterectomy for pure ureter cancer. ( 24202956 )
2013
2
Papillary urothelial carcinoma in sigmoid neobladder suggesting 'intraluminal seeding' from ureter cancer. ( 19138291 )
2008
3
Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer. ( 17725112 )
2007
4
The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. ( 2606581 )
1989
5
The Copenhagen case-control study of renal pelvis and ureter cancer: role of smoking and occupational exposures. ( 3356489 )
1988

Variations for Ureter Cancer

Expression for Ureter Cancer

Search GEO for disease gene expression data for Ureter Cancer.

Pathways for Ureter Cancer

Pathways related to Ureter Cancer according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.22 MGP PLAU
2 11.17 PLAU TERT
3 11.11 PLAU PLAUR
4 10.94 PLAU PLAUR
5 10.83 PLAU PLAUR
6 10.33 MGP PLAU PLAUR
7 10.07 PLAU PLAUR

GO Terms for Ureter Cancer

Cellular components related to Ureter Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 specific granule membrane GO:0035579 8.62 PLAU PLAUR

Biological processes related to Ureter Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.96 PLAU PLAUR
2 positive regulation of cardiac muscle contraction GO:0060452 8.62 ADRA1A CHGA

Sources for Ureter Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....